Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
116961092 | 11696109 | 2 | F | 201402 | 20160822 | 20151104 | 20160830 | EXP | US-JNJFOC-20151100047 | JANSSEN | 56.27 | YR | A | M | Y | 0.00000 | 20160830 | CN | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
116961092 | 11696109 | 1 | PS | INVOKANA | CANAGLIFLOZIN | 1 | Oral | N | 204042 | 100 | MG | TABLET | QD | ||||||
116961092 | 11696109 | 2 | SS | METFORMIN | METFORMIN HYDROCHLORIDE | 1 | Unknown | 0 | 1000 | MG | UNSPECIFIED | BID | |||||||
116961092 | 11696109 | 3 | SS | ONGLYZA | SAXAGLIPTIN HYDROCHLORIDE | 1 | Unknown | U | 0 | UNSPECIFIED |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
116961092 | 11696109 | 1 | Type 2 diabetes mellitus |
116961092 | 11696109 | 2 | Diabetes mellitus |
116961092 | 11696109 | 3 | Diabetes mellitus |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
116961092 | 11696109 | OT |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
116961092 | 11696109 | Diabetic ketoacidosis | |
116961092 | 11696109 | Myocardial infarction | |
116961092 | 11696109 | Renal injury |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
116961092 | 11696109 | 1 | 2013 | 0 |